Top Markets
#1 MowCat MowCat +48.96%
#2 Audiera Audiera +28.09%
#3 Velvet Velvet +27.19%
#4 Bermuda Shorts Bermuda Shorts +24.66%
#5 aPriori aPriori +22.35%
#6 Quack AI Quack AI +21.37%
#7 Biconomy Biconomy +20.22%
#8 Derive Derive +19.47%
#9 SkyAI SkyAI +14.66%
#10 Geodnet Geodnet +12.98%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Rank in Stocks #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Share Price
$2.70
Last synced: 2023-05-17
Market Cap
$4.13M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Graybug Vision, Inc. (GRAY)

Category

Healthcare
P/B ratio for Graybug Vision, Inc. (GRAY)
P/B ratio as of 2026 TTM: 0
According to Graybug Vision, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Graybug Vision, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE